Literature DB >> 3829297

The effects of cremophor EL in the anaesthetized dog.

J H Gaudy, J F Sicard, F Lhoste, J F Boitier.   

Abstract

The effects of cremophor EL were studied in 13 anaesthetized, paralyzed and ventilated dogs. Twenty per cent cremophor EL in a dose of 4.3 +/- 0.92 ml was infused at a rate of 30 ml X hr-1. In seven dogs, thoracopulmonary compliance, heart rate, systemic arterial pressure (SAP), pulmonary pressures (PAP, PCWP, RAP), cardiac output (CO) and platelet and white cell counts, were measured before the injection of cremophor EL, at the end of infusion and 5, 10, 30 and 150 minutes after the end of infusion. In six dogs, SAP, CO, and blood volume were measured before the injection of cremophor EL, at the end of infusion and 10, 30, 90 and 150 minutes after the end of infusion. Plasma histamine and catecholamines were assayed before the injection of cremophor EL and 2, 5, 10, 30, 90 and 150 minutes after starting the infusion. Cremophor EL induced a marked, sustained and significant decrease in SAP at the end of infusion and at 5, 10 and 30 minutes after the completion of the infusion (-68, -71, -70 and -43 per cent respectively), in PCWP, RAP and CO (-78 per cent at the end of infusion, -32 per cent 150 minutes after the end of infusion). Heart rate and systemic vascular resistance did not vary significantly. Pulmonary vascular resistance increased at the end of infusion, five and ten minutes after the end of infusion (+734, +548 and +439 per cent respectively). Plasma volume decreased 10 and 30 minutes after the end of infusion (-28 and -30.5 per cent respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829297     DOI: 10.1007/BF03015328

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  31 in total

1.  Myocardial substrate utilization in anaphylactic shock.

Authors:  J J Spitzer
Journal:  Proc Soc Exp Biol Med       Date:  1976-01

Review 2.  Allergic reactions during anesthesia.

Authors:  R K Stoelting
Journal:  Anesth Analg       Date:  1983-03       Impact factor: 5.108

3.  Hypovolemia and permeability pulmonary edema associated with anaphylaxis.

Authors:  R W Carlson; R C Schaeffer; V K Puri; A P Brennan; M H Weil
Journal:  Crit Care Med       Date:  1981-12       Impact factor: 7.598

4.  Venous plasma histamine in exercise- and hyperventilation-induced asthma in man.

Authors:  P J Barnes; M J Brown
Journal:  Clin Sci (Lond)       Date:  1981-08       Impact factor: 6.124

5.  Blood volume replacement in acute anaphylactic cardiovascular collapse related to anaesthesia.

Authors:  M Fisher
Journal:  Br J Anaesth       Date:  1977-10       Impact factor: 9.166

6.  Hemodynamic changes in human anaphylaxis.

Authors:  H J Silverman; C Van Hook; E F Haponik
Journal:  Am J Med       Date:  1984-08       Impact factor: 4.965

7.  Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity.

Authors:  W Lorenz; A Schmal; H Schult; S Lang; C Ohmann; D Weber; B Kapp; L Lüben; A Doenicke
Journal:  Agents Actions       Date:  1982-04

8.  Novel double-isotope technique for enzymatic assay of catecholamines, permitting high precision, sensitivity and plasma sample capacity.

Authors:  M J Brown; D A Jenner
Journal:  Clin Sci (Lond)       Date:  1981-11       Impact factor: 6.124

9.  [Respiratory effects of increasing doses of alfathesin in the dog].

Authors:  J H Gaudy; C Dauthier; J F Boitier; F Ferracci
Journal:  Can Anaesth Soc J       Date:  1982-11

10.  A novel double-isotope technique for the enzymatic assay of plasma histamine: application to estimation of mast cell activation assessed by antigen challenge in asthmatics.

Authors:  M J Brown; P W Ind; R Causon; T H Lee
Journal:  J Allergy Clin Immunol       Date:  1982-01       Impact factor: 10.793

View more
  8 in total

Review 1.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

2.  Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia.

Authors:  H L McLeod; D K Baker; C H Pui; J H Rodman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Hypersensitivity reaction to intravenous but not oral tacrolimus.

Authors:  Sarah Nicolai; Supinda Bunyavanich
Journal:  Transplantation       Date:  2012-11-15       Impact factor: 4.939

4.  Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.

Authors:  M E Dolan; A E Pegg; R C Moschel; B R Vishnuvajjala; K P Flora; M R Grever; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Effects of polysorbates and Cremophor EL on vascular responses in rat aorta.

Authors:  H Zengil; U Hodoğlugil; Z Güney
Journal:  Experientia       Date:  1995-11-15

6.  Overview of the marmoset as a model in nonclinical development of pharmaceutical products.

Authors:  Antonia Orsi; Daryl Rees; Isabella Andreini; Silvana Venturella; Serena Cinelli; Germano Oberto
Journal:  Regul Toxicol Pharmacol       Date:  2010-12-13       Impact factor: 3.271

7.  Intravenous tacrolimus and cyclosporine induced anaphylaxis: what is next?

Authors:  Sung-Yoon Kang; Kyoung-Hee Sohn; Jeong-Ok Lee; Sae-Hoon Kim; Sang-Heon Cho; Yoon-Seok Chang
Journal:  Asia Pac Allergy       Date:  2015-07-29

8.  Use of oral paclitaxel for the treatment of bladder tumors in dogs.

Authors:  Hyung-Kyu Chae; Ji-In Yang; Ju-Hyun An; In-Hyun Lee; Min-Hee Son; Woo-Jin Song; Hwa-Young Youn
Journal:  J Vet Med Sci       Date:  2020-04-03       Impact factor: 1.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.